Joseph CPA - Inhibikase TherapeuticsInc Chief Officer
| IKT Stock | USD 1.89 0.03 1.61% |
Insider
Joseph CPA is Chief Officer of Inhibikase TherapeuticsInc
| Age | 62 |
| Phone | 678 392 3419 |
| Web | https://www.inhibikase.com |
Inhibikase TherapeuticsInc Management Efficiency
The company has Return on Asset of (0.6423) % which means that on every $100 spent on assets, it lost $0.6423. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.1964) %, meaning that it generated no profit with money invested by stockholders. Inhibikase TherapeuticsInc's management efficiency ratios could be used to measure how well Inhibikase TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Arnold Levine | Pmv PharmaceuticalsInc | 84 | |
| FACP FACP | Oncolytics Biotech | 74 | |
| Thomas Shenk | Pmv PharmaceuticalsInc | 77 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| David Mack | Pmv PharmaceuticalsInc | 62 | |
| Ramtin MD | RenovoRx | 57 | |
| Leila MD | Pmv PharmaceuticalsInc | 61 | |
| CA CA | Oncolytics Biotech | N/A | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Gerald Goodman | Nutriband | 76 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| KwanHong MD | Longeveron LLC | 57 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
Management Performance
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.64 |
Inhibikase TherapeuticsInc Leadership Team
Elected by the shareholders, the Inhibikase TherapeuticsInc's board of directors comprises two types of representatives: Inhibikase TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inhibikase. The board's role is to monitor Inhibikase TherapeuticsInc's management team and ensure that shareholders' interests are well served. Inhibikase TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inhibikase TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Rush, Head Research | ||
| Milton Werner, President CEO | ||
| BSc FRCPC, Interim Advisor | ||
| Garth LeesRolfe, Chief Officer | ||
| Joseph CPA, Chief Officer | ||
| Surendra Singh, Manufacturing Chemistry | ||
| Dan Williams, Controller |
Inhibikase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inhibikase TherapeuticsInc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (102.85) % | ||||
| Current Valuation | 2.98 M | ||||
| Shares Outstanding | 6.48 M | ||||
| Shares Owned By Insiders | 13.85 % | ||||
| Shares Owned By Institutions | 9.12 % | ||||
| Number Of Shares Shorted | 135.25 K | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 55.21 X |
Pair Trading with Inhibikase TherapeuticsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inhibikase TherapeuticsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase TherapeuticsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Inhibikase Stock
| 0.67 | EQ | Equillium | PairCorr |
Moving against Inhibikase Stock
| 0.69 | VERU | Veru Inc Fiscal Year End 13th of December 2024 | PairCorr |
| 0.42 | YS | YS Biopharma | PairCorr |
The ability to find closely correlated positions to Inhibikase TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inhibikase TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inhibikase TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inhibikase TherapeuticsInc to buy it.
The correlation of Inhibikase TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inhibikase TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inhibikase TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inhibikase TherapeuticsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Inhibikase Stock analysis
When running Inhibikase TherapeuticsInc's price analysis, check to measure Inhibikase TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase TherapeuticsInc is operating at the current time. Most of Inhibikase TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Inhibikase TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase TherapeuticsInc's price. Additionally, you may evaluate how the addition of Inhibikase TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Inhibikase TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase TherapeuticsInc. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibikase TherapeuticsInc is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Inhibikase TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase TherapeuticsInc's market value can be influenced by many factors that don't directly affect Inhibikase TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.